Immusoft Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $4.58M

  • Investors
  • 28

Immusoft General Information

Description

Developer of novel therapies designed for the treatment of rare diseases. The company develops autologous cell therapies based on its immune system programming technology that entails collecting a type of the patient's immune cells, called B cells which can turn into bio factories each of which manufactures and secretes various antibodies, enabling the medical community to combat infectious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 454 North 34th Street
  • Seattle, WA 98103
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 454 North 34th Street
  • Seattle, WA 98103
  • United States
+1 (206)

Immusoft Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immusoft Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC (Series B) 15-Mar-2025 $4.58M Completed Clinical Trials - Phase 1
13. Grant 29-Jan-2023 Completed Clinical Trials - Phase 1
12. Secondary Transaction - Private 30-May-2022 Completed Clinical Trials - Phase 1
11. Grant 23-Nov-2021 Completed Clinical Trials - Phase 1
10. Later Stage VC (Series B) 02-Mar-2021 Completed Clinical Trials - Phase 1
9. Grant 30-Sep-2020 Completed Clinical Trials - Phase 1
8. Grant 25-Sep-2020 Completed Clinical Trials - Phase 1
7. Debt - PPP 13-Apr-2020 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series B) 01-Jan-2020 $33M $39.9M Completed Clinical Trials - Phase 1
5. Grant 05-Sep-2018 $3.59M $6.92M Completed Clinical Trials - Phase 1
To view Immusoft’s complete valuation and funding history, request access »

Immusoft Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A3
Series A2
Series A1 915,356 $0.000100 $0.02 $0.33 $0.33 1x $0.33 0.53%
Series A 1,865,653 $0.000100 $0.02 $0.15 $0.15 1x $0.15 1.09%
To view Immusoft’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Immusoft Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapies designed for the treatment of rare diseases. The company develops autologous cell therapies
Drug Discovery
Seattle, WA
22 As of 2025

Cambridge, MA
 

Madison, WI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immusoft Competitors (42)

One of Immusoft’s 42 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Centrose Venture Capital-Backed Madison, WI
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Attune Pharmaceuticals Venture Capital-Backed New York, NY
Selecta Biosciences Formerly VC-backed Watertown, MA
You’re viewing 5 of 42 competitors. Get the full list »

Immusoft Patents

Immusoft Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026085108-A2 B cell compositions and methods of use Pending 14-Oct-2024
WO-2026085108-A3 B cell compositions and methods of use Pending 14-Oct-2024
EP-4836799-A2 Glp-1 expressing modified b cells for the treatment of metabolic disease Pending 05-Jan-2024
WO-2025147573-A2 Glp-1 expressing modified b cells for the treatment of metabolic disease Inactive 05-Jan-2024
WO-2025147573-A3 Glp-1 expressing modified b cells for the treatment of metabolic disease Inactive 05-Jan-2024 C12N5/0635
To view Immusoft’s complete patent history, request access »

Immusoft Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immusoft Investors (28)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioRock Ventures Venture Capital Minority
Biovision Ventures Venture Capital Minority
Michigan Capital Network Venture Capital Minority
NYBC Ventures Corporate Venture Capital Minority
RV Invest Corporate Venture Capital Minority
You’re viewing 5 of 28 investors. Get the full list »

Immusoft Investments & Acquisitions (2)

Immusoft’s most recent deal was a Corporate Asset Purchase with Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells). The deal was made on 27-Mar-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) 27-Mar-2023 Corporate Asset Purchase Buildings and Property
Discoverygenomics.net 08-Mar-2016 Merger/Acquisition Drug Delivery
To view Immusoft’s complete investments and acquisitions history, request access »

Immusoft FAQs

  • When was Immusoft founded?

    Immusoft was founded in 2009.

  • Where is Immusoft headquartered?

    Immusoft is headquartered in Seattle, WA.

  • What is the size of Immusoft?

    Immusoft has 22 total employees.

  • What industry is Immusoft in?

    Immusoft’s primary industry is Drug Discovery.

  • Is Immusoft a private or public company?

    Immusoft is a Private company.

  • What is the current valuation of Immusoft?

    The current valuation of Immusoft is .

  • What is Immusoft’s current revenue?

    The current revenue for Immusoft is .

  • How much funding has Immusoft raised over time?

    Immusoft has raised $54.8M.

  • Who are Immusoft’s investors?

    BioRock Ventures, Biovision Ventures, Michigan Capital Network, NYBC Ventures, and RV Invest are 5 of 28 investors who have invested in Immusoft.

  • Who are Immusoft’s competitors?

    Marengo Therapeutics, Centrose, Inovio Pharmaceuticals, Attune Pharmaceuticals, and Selecta Biosciences are some of the 42 competitors of Immusoft.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process